| __timestamp | Amneal Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 5758000 |
| Thursday, January 1, 2015 | 367054000 | 8423000 |
| Friday, January 1, 2016 | 420770000 | 11986000 |
| Sunday, January 1, 2017 | 507476000 | 15215000 |
| Monday, January 1, 2018 | 946588000 | 15356000 |
| Tuesday, January 1, 2019 | 1273376000 | 16660000 |
| Wednesday, January 1, 2020 | 1364130000 | 52459000 |
| Friday, January 1, 2021 | 1324696000 | 75061000 |
| Saturday, January 1, 2022 | 1427596000 | 87221000 |
| Sunday, January 1, 2023 | 1573042000 | 83779000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. From 2014 to 2023, Amneal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have showcased contrasting trends in their cost of revenue. Amneal's cost of revenue surged by approximately 368%, peaking in 2023, while Supernus experienced a more modest increase of around 135% over the same period. This stark difference highlights Amneal's aggressive expansion strategy, reflected in its higher cost base. Meanwhile, Supernus's steady growth suggests a more conservative approach, focusing on optimizing existing operations. The data reveals that Amneal's cost of revenue consistently outpaced Supernus's by a factor of nearly 20, underscoring the scale at which Amneal operates. As the pharmaceutical industry continues to evolve, understanding these financial dynamics is crucial for stakeholders aiming to navigate this complex market.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Sanofi and Amneal Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Regeneron Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
ADMA Biologics, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Gross Profit Comparison: Amneal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. Trends
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses